Eligibility criteria: First, we identified patients meeting claims-based criteria for T2D between 01/01/2011 and 12/31/2019, using International Classification of Disease, Ninth/Tenth Revision, Clinical Modification (ICD-9/10-CM) diagnosis codes occurred at the primary or secondary position from inpatient, outpatient or carrier claims (Supplement Table 2)
That means its available without a prescription, including through (less-than-reputable) online vendors, but is suitable for laboratory use only because of relatively low purity levels.27 If you were to take research-grade DSIP, you run a higher risk of experiencing an anaphylaxis-like immunogenetic reaction
That level of disclosure is almost unheard of in this category
We still need more study to understand how GIP affects fat metabolism in humans
It's a model that makes treatment accessible to a much broader audience who may have been shut out by insurance denials or high retail prices